Literature DB >> 27240121

Postoperative Strokes and Intracranial Bleeds in Patients With Atrial Fibrillation: The FibStroke Study.

Antti Palomäki1, Tuomas Kiviniemi1, Juha E K Hartikainen2, Pirjo Mustonen3, Antti Ylitalo4, Ilpo Nuotio5, Päivi Hartikainen2,6, Jussi Jaakkola1, Riho Luite2, K E Juhani Airaksinen1.   

Abstract

BACKGROUND: Patients with atrial fibrillation (AF) frequently undergo invasive procedures. Optimal perioperative use of oral anticoagulation (OAC) and heparin bridging is not well defined. HYPOTHESIS: Discontinuation of OAC for minor procedures/operations places AF patients at risk for thromboembolism.
METHODS: In this study, we assessed perioperative antithrombotic treatment in patients with AF who suffered a postoperative stroke or intracranial bleeding. The FibStroke Study includes AF patients with an ischemic stroke or intracranial bleed identified from the discharge registries of 4 Finnish hospitals. In total, 3632 consecutive patients developed 3252 ischemic strokes and 794 intracranial bleeds. All invasive procedures during the 30 days preceding the stroke or intracranial bleed were identified.
RESULTS: A total of 194/3252 (6.0%) ischemic strokes and 23/794 (2.9%) intracranial bleeds were preceded by a procedure. Altogether, 69% of the patients were on OAC prior to index procedure, OAC was interrupted in 81.2% of the procedures preceding a stroke, and heparin bridging was used in 27.8% of interruptions. Of the procedures leading to stroke, 42.3% were low-bleeding-risk procedures, and OAC was interrupted in 84.7% of these procedures. The median time from procedure to stroke was 4 days. Heparin bridging was used in 54.5% of OAC interruptions preceding intracranial bleeding and combination of anticoagulation with antiplatelet therapy by 43.5% of patients with postoperative intracranial bleeding.
CONCLUSIONS: Perioperative interruption of OAC is common in patients who suffer a postoperative stroke, even in patients with low-bleeding-risk procedures. Postoperative intracranial bleeding is frequently preceded by perioperative heparin bridging.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27240121      PMCID: PMC6490869          DOI: 10.1002/clc.22554

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  22 in total

1.  Management of antithrombotic agents for endoscopic procedures.

Authors:  Michelle A Anderson; Tamir Ben-Menachem; S Ian Gan; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; David R Lichtenstein; John T Maple; Bo Shen; Laura Strohmeyer; Todd Baron; Jason A Dominitz
Journal:  Gastrointest Endosc       Date:  2009-11-03       Impact factor: 9.427

2.  Pacemaker or defibrillator surgery without interruption of anticoagulation.

Authors:  David H Birnie; Jeff S Healey; George A Wells; Atul Verma; Anthony S Tang; Andrew D Krahn; Christopher S Simpson; Felix Ayala-Paredes; Benoit Coutu; Tiago L L Leiria; Vidal Essebag
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

Review 3.  Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis.

Authors:  Erin Jamula; Nancy S Lloyd; Jon-David Schwalm; K E Juhani Airaksinen; James D Douketis
Journal:  Chest       Date:  2010-04-30       Impact factor: 9.410

4.  Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

Authors:  Jeff S Healey; John Eikelboom; James Douketis; Lars Wallentin; Jonas Oldgren; Sean Yang; Ellison Themeles; Hein Heidbuchel; Hein Heidbuchle; Alvaro Avezum; Paul Reilly; Stuart J Connolly; Salim Yusuf; Michael Ezekowitz
Journal:  Circulation       Date:  2012-06-14       Impact factor: 29.690

Review 5.  How I treat anticoagulated patients undergoing an elective procedure or surgery.

Authors:  Alex C Spyropoulos; James D Douketis
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

6.  Safety of coronary artery bypass surgery during therapeutic oral anticoagulation.

Authors:  K E Juhani Airaksinen; Fausto Biancari; Pasi Karjalainen; Reija Mikkola; Kari Kuttila; Pekka Porela; Timo Laitio; Gregory Y H Lip
Journal:  Thromb Res       Date:  2011-06-17       Impact factor: 3.944

7.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

8.  Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment.

Authors:  Antti-Pekka Annala; Pasi P Karjalainen; Pekka Porela; Kai Nyman; Antti Ylitalo; K E Juhani Airaksinen
Journal:  Am J Cardiol       Date:  2008-05-22       Impact factor: 2.778

Review 9.  Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

Authors:  Deborah Siegal; Jovana Yudin; Scott Kaatz; James D Douketis; Wendy Lim; Alex C Spyropoulos
Journal:  Circulation       Date:  2012-08-21       Impact factor: 29.690

10.  Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth.

Authors:  Branislav V Bajkin; Stevan L Popovic; Srecko D J Selakovic
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.